Organisation paid for research Program year 2025 Source: CMS Open Payments

Adams Clinical Inc

Neither a doctor nor a teaching hospital

Research payments

$27,290,716

162 payments

Through program year 2025, Adams Clinical Inc is reported as receiving $27,290,716 in research payments, across 162 payments.

By program year

3 rows

Year	Kind	Amount	Payments
2025	Research	$8,512,536	84
2024	Research	$8,693,050	52
2023	Research	$10,085,131	26

Breakdown

Who paid Research payments · program years 2023–2025

Eli Lilly and Company $21,905,806 27 payments
Boehringer Ingelheim Pharmaceuticals, Inc. $1,893,720 31 payments
AbbVie, Inc. $1,523,394 28 payments
Roche Diagnostics Operations, Inc. $1,221,238 23 payments
Janssen Research & Development, LLC $658,430 46 payments
Roche Molecular Systems, Inc. $88,129 7 payments

Studies the money was for Research payments · program years 2023–2025

A Study of Different Donanemab (Ly3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (Trailblazer-Alz 6) $5,474,270 2 payments
A Study of Different Donanemab (Ly3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (Trailblazer-Alz 6) $5,081,923 4 payments
A Study of Remternetug Versus Placebo in Early Alzheimer's Disease Participants at Risk for Cognitive and Functional Decline $3,171,201 4 payments
Assessment of Safety, Tolerability, and Efficacy Measured By Amyloid Reduction of Ly3372993 in Early Symptomatic Alzheimer's Disease $3,012,920 4 payments
Assessment of Safety Tolerability and Efficacy Measured By Amyloid Reduction of Ly3372993 in Early Symptomatic Alzheimer's Disease $2,342,833 2 payments
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder $1,893,720 31 payments
Rd006263 $1,221,220 22 payments
A Study of Donanemab (Ly3002813) in Participants With Early Alzheimer's Disease (Trailblazer-Alz 2) $811,549 1 payment
Assessment of Safety, Tolerability, and Efficacy of Ly3372689 in Early Symptomatic Alzheimer's Disease $714,294 2 payments
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimers Disease $621,988 11 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.